Quick Answer
PLIANT THERAPEUTICS, INC. reported Diluted EPS of $2.43 per share (loss) for fiscal year 2025.
PLIANT THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.43 | +30.0% |
| 2024 | -$3.47 | -26.2% |
| 2023 | -$2.75 | +6.5% |
| 2022 | -$2.94 | -8.5% |
| 2021 | -$2.71 | -39.0% |
| 2020 | -$1.95 | +53.8% |
| 2019 | -$4.22 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.43 | +54.7% | +39.4% |
| June 30, 2025 | -$0.71 | +22.8% | +22.8% |
| March 31, 2025 | -$0.92 | -17.9% | +3.2% |
| September 30, 2024 | -$0.95 | -35.7% | -3.3% |
| June 30, 2024 | -$0.92 | -31.4% | -17.9% |
| March 31, 2024 | -$0.78 | -16.4% | -11.4% |
| September 30, 2023 | -$0.70 | -7.7% | +0.0% |
| June 30, 2023 | -$0.70 | +14.6% | -4.5% |
- PLIANT THERAPEUTICS, INC. showed an increase of +30.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, PLIANT THERAPEUTICS, INC.’s diluted eps has grown by 42.4% (from $4.22 per share (loss) to $2.43 per share (loss)).
- The most recent figure is from PLIANT THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: